WallStreetZenWallStreetZen

NASDAQ: CRSP
Crispr Therapeutics Ag Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Crispr Therapeutics Ag revenue was $37.31M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $35.7M, up 5,828.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CRSP annual revenue was $37.3M, with -89.9% growth year-over-year.

CRSP past revenue growth

How has CRSP's revenue growth performed historically?

Company
-89.95%
Industry
479.21%
Market
20.62%
CRSP's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CRSP's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CRSP's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CRSP revenue history

Current Revenue
$37.3M
Current Earnings
-$366.3M
Current Profit Margin
-981.5%

Be the first to know when CRSP announces revenue.

CRSP Revenue History By Year

CRSP Yearly RevenueCRSP RevenueCRSP ChangeCRSP Revenue Growth
2024-12-31$37.31M-$333.89M-89.95%
2023-12-31$371.21M$370.01M+30,885.48%
2022-12-31$1.20M-$913.77M-99.87%
2021-12-31$914.96M$914.24M+127,154.94%
2020-12-31$719.00k-$288.87M-99.75%
2019-12-31$289.59M$286.47M+9,169.85%
2018-12-31$3.12M-$37.87M-92.38%
2017-12-31$41.00M$35.83M+693.90%
2016-12-31$5.16M$4.92M+1,990.69%
2015-12-31$247.00kN/AN/A
2014-12-31$0.00N/AN/A

1 of 1

Crispr Therapeutics Ag Revenue FAQ

What was CRSP's revenue last quarter?

On Invalid Date, Crispr Therapeutics Ag (NASDAQ: CRSP) reported Q4 2024 revenue of $35.69 million up 82.26% year over year. In the same quarter last year, Crispr Therapeutics Ag's revenue was $201.21 million.

What was Crispr Therapeutics Ag's revenue in 2024?

Crispr Therapeutics Ag's annual revenue for the twelve months ending Dec 31, 2024 was $37.31 million, a 89.95% decrease year over year.

How much does Crispr Therapeutics Ag make in a day?

Based on Crispr Therapeutics Ag annual revenue for the past five years, CRSP makes an average of $726,246.58 per day.

What was Crispr Therapeutics Ag's annual revenue growth in the past year?

As of Q2 2025, Crispr Therapeutics Ag's revenue has grown -89.95% year over year. This is 569.16 percentage points lower than the US Biotechnology industry revenue growth rate of 479.21%. Crispr Therapeutics Ag's revenue in the past year totaled $37.31 million.

How much does Crispr Therapeutics Ag make in a year?

Crispr Therapeutics Ag's revenue by year for the past five years is:
  • Crispr Therapeutics Ag's revenue for the twelve months ending Dec 31, 2024 was $37.31 million, a 89.95% decrease year over year.
  • Crispr Therapeutics Ag's annual revenue for Dec 31, 2023 was $371.21 million, a 30,885.48% increase from 2022.
  • Crispr Therapeutics Ag's annual revenue for 2022 was $1.20 million, a 99.87% decrease from 2021.
  • Crispr Therapeutics Ag's annual revenue for 2021 was $914.96 million, a 127,154.94% increase from 2020.
  • Crispr Therapeutics Ag's annual revenue for 2020 was $719.00 thousand, a 99.75% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.